Drug intelligence / Profile preview

TP-122

Development stage: Unknown
Lead developer: TechnoPhage
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Inhalation

Overview

TP-122 is an investigational **bacteriophage cocktail** developed by TechnoPhage for ventilator-associated pneumonia caused by Gram-negative pathogens. The full cocktail contains two components: TP-122A, comprising three lytic bacteriophages directed against *Pseudomonas aeruginosa*, and TP-122B, comprising three bacteriophages directed against *Klebsiella pneumoniae*. Its clinical program is evaluating nebulized TP-122A, the anti-*P. aeruginosa* component, added to standard care for ventilator-associated pneumonia. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06370598))

Targets

P. aeruginosa (Pseudomonas aeruginosa)

Beyond the preview

Go deeper on TP-122.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TP-122.

Explore the full profile